|
|
Article: Lilly Plans to Submit Cymbalta(R) (duloxetine hydrochloride) New Drug Application for Generalized Anxiety Disorder.
- Article from:
- PR Newswire
- Article date:
- December 9, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Four Million Americans Are Diagnosed Annually With Generalized Anxiety Disorder
INDIANAPOLIS, Dec. 9 /PRNewswire-FirstCall/ -- Eli Lilly and Company plans to submit a supplemental New Drug Application (sNDA) in 2006 to the Food and Drug Administration for Cymbalta(R) (duloxetine hydrochloride) for the treatment of generalized anxiety disorder (GAD). Lilly has completed two clinical trials, which the company believes will support this submission.
"People with generalized anxiety disorder experience a wide array of symptoms from excessive worry to difficulty concentrating. In addition, it is also common for patients to experience physical symptoms like ...